Financial Personal
Aptose Announces First AML Patients Dosed with Tuspetinib Triplet Frontline Therapy in TUSCANY Trial
TUS+VEN+AZA triplet has potential as frontline therapy to treat large, mutationally diverse populations of AML SAN DIEGO and TORONTO, Jan. 09, 2025 (GLOBE NEWSWIRE) — Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS),
TUS+VEN+AZA triplet has potential as frontline therapy to treat large, mutationally diverse populations of AML Read More
